NICB

Selected Peer Reviewed Journals

• Prof Martin Clynes. .
• Prof Martin Clynes. .
• Prof Martin Clynes. .
• Breen L, Keenan J, Clynes M. 2011. Generation of lung cancer cell line variants by drug selection or cloning. Methods And Applications Of Analtsis, 731,, pp125-33.
• Barron N, Keenan J, Gammell P, Martiniz VG, Freeman A, Masters JR, Clynes M. 2011. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.
• Clarke C, Doolan P, Barron N, Meleady P, Madden SF, Dinino D, Leonard M, Clynes M. 2011. CGCDB: A web-based resource for the investigation of gene coexpression in CHO cell culture. Biotechnology And Bioengineering,
• Doolan P, Barron N, Kinsella P, Clarke C, Meleady P, O'Sullivan F, Melville M, Leonard M, Clynes M. 2011. Microarray expression profiling identifies genes regulating sustained cell specific productivity (S-Qp) in CHO K1 production cell lines. Journal Of Biotechnology,
• Reeves EP, Bergin DA, Fitzgerald S, Hayes E, Keenan J, Henry M, Meleady P, Vega-Carrascal I, Murray MA, Low TB, McCarthy C, O'Brien E, Clynes M, Gunaratnam C, McElvaney NG. 2011. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis.
• Clarke C, Doolan P, Barron N, Melady P, O'Sullivan F, Gammell P, Melville M, Leonard M, Clynes M. 2011. Large scale microarray profiling and coexpression network analysis of CHO cells identifies transcriptional modules associated with growth and productivity. Journal Of Biotechnology, 155, 3, pp350-9.
• Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M. 2011. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast ,colorectal and lung cancer. International Journal Of Cancer,
• Melville M, Doolan P, Mounts W, Barron N, Hann L, Leonard M, Clynes M, Charlebois T. 2011. Development and characterization of a Chinese hamster ovary cell-specific oligonucleotide microarray. Biotechnology Letters, 33, 9, pp1773-9.
• Meleady P, Doolan P, Henry M, Barron N, Keenan J, O'Sullivan F, clarke C, Gammell P, Melville MW, Leonard M, Clynes M. 2011. Sustained productivity in recombinant Chinese hamster ovary (CHO) cell lines: proteome analysis of the molecular basis for a process-related phenotype. Bmc Biotechnology, 24, 11, pp78-.
• Walsh N, Larkin A, Swan N, Conlon K, Dowling P, McDermott R, Clynes M. 2011. RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Letters, 306, 2, pp180-9.
• Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. 2011. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. International Journal Of Cancer,
• Eustace AJ, Dowling P, Henry M, Doolan P, Meleady P, Clynes M, Crown J, O'Donovan N. 2011. 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines. Proteomics, 74, 4, pp490-501.
• Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M. 2011. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics, 11, 8, pp1391-402.
• Dowling P, Clynes M. 2011. Conditioned media from celllines: a complementary model to clinical speciments for the discovery of disease-specific biomarkers. Proteomics, 11, 4, pp794-804.
• Barron N, Kumar N, Sanchez N, Doolan P, Clarke C, Meleady P, O'Sullivan F, Clynes M. 2011. Engineering CHO cell growth and recombinant protein productivity by overexpression of miR-7. Journal Of Biotechnology, 151, 2, pp204-211.
• Clarke C, Doolan P, Barron N, Meleady P, O'Sullivan F, Gammell P, Melville M, Leonard M, Clynes M. 2011. Predicting cell-specific productivity from CHO gene expression. Journal Of Biotechnology, 151, 2, pp159-165.
• Muniyappa MK, Dowling P, Henry M, Meleady P, Doolan P, Gammell P, Clynes M, Barron N. 2010. MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell lines. European Journal Of Cancer, 45, 17, pp3104-3118.
• Barron N, Sanchez N, Kelly P, Clynes M. 2010. MicroRNAs: tiny targets for engineering CHO cell phenotypes?. Biotechnology Letters, [Epub ahead of print],
• Dowling P, Meleady P, Henry M, Clynes M. 2010. Recent advances in clinical proteomics using mass spectrometry. Bioanalysis, 2, 9, pp1609-1615.
• Doolan P, Meleady P, Barron N, Henry M, Gallagher R, Gammell P, Melville M, Sinacore M, McCarthy K, Leonard M, Charlebois T, Clynes M. 2010. Microarray and proteomics expression profiling identifies several candidates, including the valosin-containing protein (VCP), involved in regulating high cellular growth rate in production CHO cell lines. Biotechnology And Bioengineering, 106, 1, pp42-56.
• Hennessy E, Clynes M, Jeppesen PB, O'Driscoll L. 2010. Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. Biochemical And Biophysical Research Communications, 396, 2, pp457-462.
• Kinsella P, Clynes M, Amberger-Murphy V. 2010. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. Journal Of Neuro-oncology, [Epub ahead of print],
• Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. 2009. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clinical Cancer Research, 15, 23, pp7153-7160.
• Roche S, McMahon G, Clynes M, O'Connor R. 2009. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Journal Of Chromatography B, 877, 31, pp3982-3990.
• Walsh N, Clynes M, Crown J, O'Donovan N. 2009. Alterations in integrin expression modulates invasion of pancreatic cancer cells. Journal Of Experimental & Clinical Cancer Research, 28, 140
• Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O'Driscoll L. 2009. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. Bmc Urology, 9, 6, pp1-7.
• Corkery, B., Crown, J., Clynes, M., O'Donovan, N. 2009. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals Of Oncology, 20, 5, pp852-857.
• Keenan, J., Murphy, L.,Henry, M.,Meleady, P., Clynes, M. 2009. Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics, 9, 6, pp1556-1566.
• Walsh,N ., O'Donovan, N., Kennedy, S., Henry, M.,Meleady, P., Clynes,M., Dowling, P.. 2009. Identification of pancreatic cancer invasion-related proteins by proteomic analysis.. Proteome Science, 7, 3
• Walsh, N., Dowling, P., O'Donovan, N., Henry, M.,Meleady, P.,Clynes, M. 2008. Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells.. Journal Of Proteomics, 71, 5, pp561-571.
• Dowling, P., Shields, W., Rani, S., Meleady, P., Henry, M., Jeppesen, P., O'Driscoll, L., Clynes, M.. 2008. Proteomic analysis of conditioned media from glucose responsive and glucose nonresponsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction. Electrophoresis, 29, 20, pp4141-4149.
• Eustace, AJ., Crown, J., Clynes, M., O'Donovan, N. 2008. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal Of Translational Medicine, 6,
• Germano, S., Clynes, M., Kennedy, S., Mehta, JP., Kenny, E., Ryan, E., Doolan, P., Gaminell, P., Joyce, H., de Villarreall, MP., Hill, A., O'Daly, B., Linehan, R., Cronin, D., Daly, C., Glynn, S., O'Driscoll, L. 2008. Novel role of Neuronal calcium sensor-1 (NCS-1) as prognostic factor and therapeutic target in breast cancer. Anticancer Research, 28, 5C, pp220-.
• Murphy, L., Henry, M., Meleady, P., Clynes, M., Keenan, J. 2008. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.. Biochimica Et Biophysica Acta-proteins And Proteomics, 1784, 9, pp1184-1191.
• Murphy, L., Henry, M., Meleady, P., Clynes, M., Keenan, J.. 2008. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochimica Et Biophysica Acta-proteins And Proteomics, 1784, 9, pp1184-1191.
• Breen, L., Murphy, L., Keenan, J., Clynes, M.. 2008. Development of taxane resistance in a panel of human lung cancer cell lines. Toxicology In Vitro, 22, 5, pp1234-1241.
• Martinez, V., Kennedy, S., Doolan, P., Gammell, P., Joyce, H., Kenny, E., Mehta, JP., Ryan, E., O'Connor, R., Crown, J., Clynes, M O'Driscoll, L. 2008. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue.. Breast Cancer Research And Treatment, 110, 3, pp521-530.
• Martinez, V., Kennedy, S., Doolan, P., Gammell, P., Joyce, H., Kenny, E., Mehta, JP, O'Connor, R., Ryan, E., Clynes, M., O'Driscoll, L. 2008. Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue. Breast Cancer Research And Treatment, 110, 3, pp521-530.
• Doolan, P., Melville, M., Gammell, P., Sinacore, M., Meleady, P., McCarthy, K., Francullo, L., Leonard, M., Charlebois, T., Clynes, M. 2008. Transcriptional profiling of gene expression changes in a PACE-transfected CHO DUKX cell line secreting high levels of rhBMP-2. Molecular Biotechnology, 39, 3, pp187-199.
• Dowling, P., Wormald, R., Meleady, P., Henry, M., Curran, A., Clynes, M.. 2008. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. Journal Of Proteomics, 71, 2, pp168-175.
• Meleady, P., Henry, M., Gammell, P., Doolan, P., Sinacore, M., Melville, M., Francullo, L., Leonard, M., Charlebois,T., Clynes, M.. 2008. Proteomic profiling of CHO cells with enhanced rhBMP-2 productivity following co-expression of PACEsol.. Proteomics, 8, 13, pp2611-2624.
• Doolan, P., Clynes, M., Kennedy, S., Mehta, JP., Crown, J., O'Driscoll, L.. 2008. Prevalence and prognostic and predictive relevance of PRAME in breast cancer.. Breast Cancer Research And Treatment, 109, 2, pp359-365.
• Kennedy, S., Clynes, M., Doolan, P., Mehta, JP., Rani, S., Crown, J., O'Driscoll, L.. 2008. SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue.. British Journal Of Cancer, 98, 10, pp1641-1645.
• Kumar, N., Gammell, P., Meleady, P., Henry, M., Clynes, M. 2008. Differential protein expression following low temperature culture of suspension CHO-K1 cells. Bmc Biotechnology, 8, , pp42-.
• Martinez, VG., Williams, KJ., Stratford, IJ., Clynes, M., O'Connor, R.. 2008. Overexpression of cytochrome P450NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved. Toxicology In Vitro, 22, 3, pp582-588.
• Martinez, VG., O'Connor, R., Liang, Y., Clynes, M.. 2008. CYPIBI expression is induced by docetaxel: effect on cell viability and drug resistance. British Journal Of Cancer, 98, 3, pp564-570.
• Glynn, SA., O'Sullivan, D., Eustace, AJ., Clynes, M., O'Donovan, N.. 2008. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.. Bmc Cancer, 8, , pp9-.
• Kumar N, Maurya P, Gammell P, Dowling P, Clynes M, Meleady P. 2008. Proteomic profiling of secreted proteins from CHO cells using Surface-Enhanced Laser desorption ionization time-of-flight mass spectrometry. Biotechnology Progress, 24, 1, pp273-278.
• Pierce, A., Barron, N., Linehan, R., Ryan, E., O'Driscoll, L., Daly, C., Clynes, M.. 2008. Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines. European Journal Of Cancer, 44, 1, pp151-159.
• Gammell P., Barron, N., Kumar, N. Clynes, M. 2007. Initial identification of low temperature and culture stage induction of miRNA expression in suspension CHO-K1 cells. Journal Of Biotechnology, 130(30), , pp213-218.
• Murphy L., Clynes M., Keenan J. 2007. Proteomic Analysis to Dissect Mitoxantrone Resistance-associated Proteins in a Squamous Lung Carcinoma. Anticancer Research, 27, , pp1277-1284.
• O'Driscoll, L., Walsh, N., Larkin, A., Ballot, J., Ooi, WS, Gullo, G., O'Connor, R., Clynes, M., Crown, J., Kennedy, S. 2007. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Research, 4B, pp2115-2120.
• O¿Connor R., Heenan M., Connolly L., Larkin A., Clynes M. 2007. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Research, 24, , pp457-464.
• O¿Driscoll L., Gammell P., Clynes M.. 2007. Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development. Transplant Proceedings, 36(4), , pp1151-1158.
• Piskareva, O., Clynes, M. and Barron, N. 2007. Detection and cloning of LINE-1 elements in CHO cells. Cytotechnology, 53, , pp75-80.
• Piskareva, O., Clynes, M. Barron, N. 2007. Detection and cloning of LINE-1 elements in CHO cells. Cytotechnology, 53, , pp75-80.
• Roy S., Kenny E., Kennedy S., Larkin A., Ballot J., Perez DeVillarreal M., Crown J., O¿Driscoll L.,. 2007. MDR1/P-glycoprotein and MRP-1 mRNA and Protein Expression in Non-Small Cell Lung Cancer. Anticancer Research, 27, , pp1325-1330.
• Dowling, P., O'Driscoll, L., Meleady, P., Henry, M., Roy, S., Ballot, J., Moriarty, M., Crown, J., Clynes, M.. 2007. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins.. Electrophoresis, 28, 23, pp4302-4310.
• Rani, S., Clynes, M., O'Driscoll, L.. 2007. Detection of almplifiable mRNA extracellular to insulin-producing cells: Potential for predicting beta cell mass and, function. Clinical Chemistry, 53, 11, pp1936-1944.
• Rani, S., Clynes,M., O'Driscoll, L. 2007. Detection of Amplifiable mRNA Extracellular to Insulin-Producing Cells: Petential for Predicting Beta Cell Mass and Function. Clinical Chemistry, 53, 11, pp1936-1944.
• McKiernan, E., O'Driscoll, L., Kasper, M., Barron, N., O'Sullivan, F., Clynes M. 2007. Directed Differentiation of Mouse Embryonic Stem Cells into Pancreatic-Like or Neuronal- and Glial-Like Phenotyprs. Tissue Engineering, 13, 10, pp2419-2430.
• Mckiernan, E., O'Driscoll, L., Kasper, M., Barron, N., O'Sullivan, F., Clynes, M.. 2007. Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes. Tissue Engineering, 13, 10, pp2419-2430.
• Doolan, P., Clynes, M., Kennedy, S., Mehta, JP, Crown, J., O'Driscoll, L. 2007. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Research And Treatment,
• O'Driscoll, L., Walsh, N., Larkin, A., Ballot, J., Ooi, WS., Gullo, G., O'Connor, R., Clynes, M., Crown, J., Kennedy, S.. 2007. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.. Anticancer Research, 27, 4B, pp2115-2120.
• Gammell, P., Barron, N., Kumar, N., Clynes, M.. 2007. Initial identification of low temperature and culture stage induction of miRNA expression in suspension CHO-K1 cells.. Journal Of Biotechnology, 130, 3, pp213-218.
• Breen, L., Doolan, P., Ryan, E., Gammell, P., Mehta, JP., Clynes, M. 2007. Microarray analysis of taxol resistant lung cancer cell lines. Anticancer Research, 27, 3A, pp1379-1379.
• Breen, L., Heenan, M., Amberger-Murphy, V., Clynes, M. 2007. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines. Anticancer Research, 3A, , pp1361-1364.
• Browne, B., O'Donovan, N., Venkatesan, N., Pegram, M., Clynes, M., Duffy, MJ., Crown, J., Slamon, DJ. 2007. The role of insulin-like growth factor I receptor (IGF-IR) in trastuzumab resistance in breast cancer cells. Anticancer Research, 27, 3A, pp1379-1379.
• Bryan, W., Dowd, A., Joyce, H., Meleady, P., Clynes, M. 2007. Proteomic analysis of DLKP and its subpopulations: DLKP-SQ, DLKP-I and DLKP-M and interpretations of altered invasion rates observed in these clones. Anticancer Research, 27, 3A, pp1379-1379.
• Bryan, W., Meleady, P., Dowd, A., Dowling, P., Clynes, M. 2007. Proteomic analysis antiproliferative effect of 5-fluorouracil on normal and cancer epithelial cells of the lung. Anticancer Research, 27, 3A, pp1377-1377.
• Devery, A., Deegan, B., Kowalska, E., Gathergood, N., O'Connor, R., Clynes, M. 2007. Macrocycles, a potential anticancer agent. Anticancer Research, 27, 3A, pp1380-1380.
• Doolan, P., Bray, I., Mehta, JP., Gammell, P., Clynes, M. 2007. Whole-genome microarray assessment of taxol- and melphalan-resistant RPMI cell lines as a model for drug-induced invasion in cancer and identification of potential therapeutic targets. Anticancer Research, 27, 3A, pp1380-1381.
• Dowling, P., Maurya, P., Meleady, P., Glynn, SA, Dowd, AJ, Henry, M., Clynes, M. 2007. Purification and identification of a 7.6-kDa protein in media conditioned by superinvasive cancer cells. Anticancer Research, 27, 3A, pp1309-1317.
• Eustace, A., O'Connor, R., Clynes, M., O'Donovan, N. 2007. Expression of ABC transporters in melanoma cell lines. Anticancer Research, 27, 3A, pp1381-1381.
• Joyce, H., Clynes, M. 2007. A cellular model system characterising the invasiveness of a human lung carcinoma cell line. Anticancer Research, 27, 3A, pp1381-1381.
• Keenan, J., Murphy, L., Clynes, M. 2007. Proteomic analysis to dissect drug-resistance associated proteins in a DLKP-mitoxantrone resistant variant. 27, 3A, pp1381-1382.
• Kinsella, P., Pilkington, G., Clynes, M., Amberger-Murphy, V. 2007. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. Anticancer Research, 27, 3A, pp1382-1382.
• Larkin, A., O'Sullivan, D., Joyce, H., Glynn, S., Clynes, M. 2007. Generation and preliminary characterisation of MAbs raised to the invasive breast cell line, MDA-MB-435-SF. Anticancer Research, 27, 3A, pp1382-1382.
• Martinez, V., O'Connor, R., Clynes, M. 2007. CYP3A4 and CYP3A5 are up-regulated in pulse-selected cell lines: Role in chemotherapy resistance.,. Anticancer Research, 27, 3A, pp1382-1383.
• Maurya, P., Meleady, P., Dowling, P., Clynes, M. 2007. Differential protein profiling of secreted proteins from human cancer cell lines by surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI). Anticancer Research, 27, 3A, pp1377-1378.
• Mehta, J.P., O'Driscoll, L., Barron, N., Doolan, P., Clynes, M. 2007. A miccroarray approach to translational medicine in breast cancer: how representative are cell line models of clinical coditions?. Anticancer Research, 27, 3A, pp1295-1300.
• Mehta, JP., Doolan, P., Clynes, M. 2007. How representative are cell line models to clinical conditions? A microarray approach to translational medicine in breast cancer. Anticancer Research, 27, 3A, pp1383-1383.
• Murphy, L., Keenan, J., Clynes, M. 2007. Proteomic analysis to dissect mitoxantrone resistance=associated proteins in a squamous lung carcinoma. Anticancer Research, 27, 3A, pp1277-1284.
• Murphy, L., Keenan, J., Clynes, M. 2007. Detection of potential drug resistance markers in lung cancer. Anticancer Research, 27, 3A, pp1383-1384.
• O'Donovan, N., Browne, B., Crown, J., Duffy, MJ., Slamon, D., Clynes, M. 2007. EGFR and HER-2 antagonists in breast cancer. Anticancer Research, 27, 3A, pp1374-1374.
• O'Sullivan, D., Breen, L., Larkin, A., Clynes, M. 2007. Comparison of in vitro invasion assay methods for characterisation of human breast and melanoma cancer cell lines. Anticancer Research, 27, 3A, pp1384-1384.
• Oglesby, I., O'Driscoll, L., Clynes, M. 2007. Optimisation of siRNA transfection and its use in characterising the role of novel targets in a range of human carcinoma cell lines. Anticancer Research, 27, 3A, pp1384-1384.
• Walsh, N., O'Donovan, N., Clynes, M. 2007. Investigation into the molecular mechanisms of altered invasion and adhesion in sub-clones of the pancreatic cancer cell line, MiaPaCa-2. Anticancer Research, 27, 3A, pp1378-1378.
• Kumar, N., Gammell, P., Clynes M. 2007. Proliferation control strategies to improve productivity and survival during CHO based production culture: A summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines. Cytotechnology, 53, (1-3), pp33-46.
• McKiernan, E., Barron, N., O'Sullivan, F., Barham, P., Clynes, M., O'Driscoll, L. 2007. Detecting de novo insulin synthesis in embryonic stem cell-derived populations. Experimental Cell Research, 313(7), , pp1405-1414.
• Wall, R., McMahon, G., Crown, J., Clynes, M., O'Connor, R. 2007. Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples.. Talanta, 72, 1, pp145-154.
• Dowling, P,, Meleady, P., Dowd, A., Henry, M., Glynn, S., Clynes. 2007. Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochemical And Biophysical Research Communications, 1774, 1
• Dowling, P., Meleady, P., Dowd, A., Henry, M., Glynn, S., Clynes, M.. 2007. Proteomic analysis of isolated membrane fractions from superinvasive cancer cells.. Biochimica Et Biophysica Acta-proteins And Proteomics, 1774, 1, pp93-101.
• O'Connor, R., O'Leary, M., Ballot, J., Collins, CD., Kinsella, P., Mager, DE., Arnold, RD., O'Driscoll, L., Larkin, A., Kennedy, S., Fennelly, D., Clynes, M., Crown, J. 2007. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.. Cancer Chemotherapy And Pharmacology, 59, 1, pp79-87.
• Joyce H* Bray I, Clynes. 2006. RNA Interference with siRNA. 3, , pp127-136.
• Keenan, J., Pearson, D., Clynes, M. 2006. The role of recombinant proteins in the development of serum-free media. Cytotechnology, 50, 1-3, pp49-56.
• Keenan, J., Pearson, D., O'Driscoll, L., Gammell, P., Clynes, M. 2006. Evaulation of recombinant human transferring (DeltaFerrin TM) as an iron chelator in serum-free media for mammalian cell culture. Cytotechnology, 51, 1, pp29-37.
• O'Driscoll, L. and Clynes, M. 2006. Biomarkers and Multiple Drug Resistance in Breast Cancer. Current Cancer Drug Targets, 6, , pp365-384.
• O'Driscoll, L., Clynes, M.. 2006. Molecular markers of multiple drug resistance in breast cancer.. Chemotherapy, 52, 3, pp125-129.
• Dowling, P., O'Driscoll, L., O'Sullivan, F., Dowd, A., Henry, M., Jeppesen, PB., Meleady, P., Clynes, M. 2006. Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress.. Proteomics, 6, 24, pp6578-6587.
• O'Driscoll, L., Gammell, P., McKiernan, E., Ryan, E Jeppesen, PB., Rani, S., Clynes, M.. 2006. Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells.. Journal Of Endocrinology, 191, 3, pp665-676.
• O'Driscoll, L., McMorrow, J., Doolan, McKiernan, E., Mehta, JP, Ryan E., Gammell, P., Joyce, H., O'Donovan, N., Walsh, N., Cynes, M. 2006. Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Molecular Cancer, 5, 74, pp665-676.
• Matthews, C., Catherwood, MA., Larkin, AM., Clynes, M., Morris, TCM., Alexander, HD. 2006. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgV(H) genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leukemia And Lymphoma, 47, 11, pp2308-2313.
• Bergin, D., Murphy, L., Keenan, J., Clynes, M.,Kavanagh, K. 2006. Pre-exposure to yeast protects larvae of Galleria mellonella from a subsequent lethal infection by Candida albicans and is mediated by the increased expression of antimicrobial peptides. Microbes And Infection, 8, 8, pp2105-2112.
• Glynn, SA., Adams, A., Gibson, B., Cronin, D., Harmey, JH.,Clynes, M.. 2006. Low adhesiveness coupled with high superinvasiveness in vitro predicts the in vivo metastatic potential of a mouse mammary adenocarcinoma cell line. Anticancer Research, 26, 2A, pp1001-1010.
• O¿Driscoll L., Kenny E., Perez De Villarreal., Clynes M. 2005. Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. 2, , pp43-52.
• Dowling, P., O'Driscoll, L., Dowd, A., Meleady, P., Clynes, M. 2005. DIGE analyses indicates phenotypic changes between glucose-responsive and glucose-non-responsive MIN-6 beta cells. 4, 8, ppS197-S197.
• Larkin, A., Moran, E., Kennedy, SM., Clynes, M.. 2005. Monoclonal antibody 5C3 raised against formalin fixed paraffin-embedded invasive breast tumour tissue: Characterisation of its reactive antigen via immunoprecipitation and internal sequencing.. Journal Of Immunological Methods, 303, 1-2, pp53-65.
• Meleady, P., Dowd, A., Dowling, P., Henry, M., O'Callaghan, M., Clynes, M. 2005. Two-dimensional difference gel electrophoresis (DIGE) of a bromodeoxyuridine-treated human lung carcinoma cell line. 4, 8, ppS121-S121.
• Clynes, M. 2004. Human Embryonic Stem Cells and Cloning; Science and Bioethics at a Crossroads. Studies, 93, , pp261-268.
• Cronin D, Daly C, O¿Doherty T, Heenan M, Scanlon KJ, Clynes M. 2004. Construction and transfection of a ribozyme targeting human caspase-3. Anticancer Research, 24(A), , pp425-431.
• Keenan J, Liang Y, Clynes M. 2004. Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants. Anticancer Research, 24(A), , pp433-440.
• O¿Driscoll L, Cronin D, Kennedy SM, Purcell R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O¿Higgins NJ, Parkinson M, Clynes M. 2004. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Research, 24(2A), , pp473-482.
• O¿Driscoll L, Gammell P, Clynes M. 2004. Mechanisms associated with loss of glucose responsiveness in beta cells. Transplant Proceedings, 36, , pp1159-1162.
• Piskareva OA, Barron N, Clynes M, Schmatchenko VV. 2004. In vivo cytoplasmic localization of the p40 protein of the L1 transposable of human genome. 395, , pp118-119.
• McCann, M., Coyle, B., McKay, S., McCormack, P., Kavanagh, K., Devereux, M., McKee, V., Kinsella, P., O'Connor, R., Clynes, M. 2004. Synthesis and X-ray crystal structure of [Ag(phendio)(2)]ClO4 (phendio=1,10-phenanthroline-5,6-dione) and its effects on fungal and mammalian cells. Biometals, 17, 6, pp635-645.
• Glynn S, Gammell P, Heenan M, O¿Connor R, Liang Y, Keenan J, Clynes M. 2004. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. British Journal Of Cancer, 91, 10, pp1800-1807.
• Larkin A, O¿Driscoll L,Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M. 2004. Investigation of MRP-1 protein and MDR-1/PGP expression in invasive breast cancer; a prognostic study. International Journal Of Cancer, 112, 2, pp286-294.
• Amberger-Murphy, V., Kinsella, P., Walsh, N., Clynes, M. 2004. Why does PCV chemotherapy not work on high -grade glioma?A possible answer and what we could learn from it. Anticancer Research, 24, 5D, pp13-.
• Jampilek, J., Dolezal, M., Kunes, J., Vichova, P., Raich, I., Jun, D., O'Connor, R., Clynes, M.. 2004. Preparation of 2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl) propionic acid (VUFB 20615) and 2-methyl-2-(4-{[4-(quinolin-2-ylmethoxy)phenyl]sulfanyl}phenyl)propionic acid (VUFB 20623) as potential antileukotrienic agents. Current Organic Chemistry, 8, 13, pp1235-1243.
• Liang Y., O¿Driscoll L, Mc.Donnell S, Duffy K, O¿Connor R, Clynes M. 2004. Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. International Journal Of Cancer, 111, 4, pp484-493.
• O'Driscoll, L., Kenny, E., de Villarreal, MP., Clynes, M. 2004. Optimisation of methods for detection of novel prognostic and predictive biomarkers in serum from cancer patients. Anticancer Research, 24, 5D, pp3583-3584.
• Jampilek J, Dolezal M, Kunes J, Vichova P, Jun D, Hanika J, O¿Connor R, Clynes M. 2004. Synthesis of (2E)-2-methyl-3- (4-([4-(quinolin-2-ylmethoxy)phenyl]sulfanyl)phenyl)prop-2-enoic acid (VUFB 20609) and 2-methyl-3-(4-([4-(quinolin-2-ylmethoxy)phenyl]sulfanyl)phenyl)propanoic acid (VUFB 20584) as potentialantileukotrienic agents. Journal Of Pharmacy And Pharmacology, 56, 6, pp783-794.
• Coyle B, Kinsella P, McCann M, Devereux M, O'Connor R, Clynes M, Kavanagh K. 2004. Induction of apoptosis in yeast and mammalian cells by exposure to 1,10-phenanthroline metal complexes. Toxicology In Vitro, 1, , pp63-70.
• O'Driscoll L, Linehan R, Clynes M. 2003. "Survivin: role in normal cells and in pathological conditions". 3, , pp131-152.
• P. Gammell, L. O'Driscoll, M. Clynes. 2003. Characterisation of BHK-21 Cells Engineered to Secrete Human Insulin. Cytotechnology, 41, 1, pp11-21.
• O'Driscoll L, Linehan R, Kennedy SM, Cronin D, Purcell R, Glynn S, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M. 2003. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Letters, 201, 2, pp225-236.
• Clynes, M., O'Connor, R., O'Driscoll, L., Daly, C., Meleady, P. 2003. Challenges in molecular analysis for individualised cancer therapy. Drug Discovery Today, 8, 12, pp531-.
• Kennedy S.M, O¿Driscoll L, Linehan R, Purcell R, Fitzsimons N, Mc Dermott E.W, Hill A.D, O¿Higgins N.J, Parkinson M, Clynes M. 2003. Prognostic importance of survivin in breast cancer. British Journal Of Cancer, 88, 7, pp1077-1083.
• O'Driscoll, L., Linehan, R., Clynes, M. 2003. Survivin: Role in normal clels and in pathological conditions. Current Cancer Drug Targets, 3, 2, pp131-152.
• Walsh D, Meleady P, Power B, Morley SJ, Clynes M. 2003. Increased levels of the translation initiation factor, elF4E, in differentiating epithelial tumour cell lines. Differentiation, 71, 2, pp126-134.
• Liang Y, McDonnell S, Clynes M. 2002. Examining the relationship between cancer invasion/metastasis and drug resistance. Current Cancer Drug Targets, 3, , pp257-277.
• Moran E., O'Keefe M., O'Connor R., Larkin A.M, Murphy P., Clynes M,. 2002. Methods for Generation of Monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid. Journal Of Immunological Methods, 271, 1-2, pp65-75.
• O¿Driscoll L, Linehan R, Liang Y, Joyce H, Oglesby I, Clynes M. 2002. Galectin-3 expression alters adhesion, motility, and invasion in a lung cell line (DLKP), in vitro. Anticancer Research, 22, 6A, pp3117-3125.
• Liang, Y., McDonnell, s., Clynes, M. 2002. Examining the relationship between cancer invasion/metastatsis and drug resistance. Current Cancer Drug Targets, 2, 3, pp257-277.
• Tuohey S, O'Connor R, Plunkett S, Maguire A, Clynes M. 2002. Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition: Identification of Novel Chemotherapeutic Drug Resistance Modulators. European Journal Of Cancer, 38, 12, pp1661-1670.
• Liang, YZ., McDonnell, S., Doolan, P., Clynes, M. 2002. Enhanced in vitro invasiveness and drug resistance in a human lung carcinoma cell line, DLKP, after treatment with mitoxantrone, 5-fluorouracil, methotrexate, BCNU, cisplatin or chlorambucil, and enhanced drug resistance but not in vitro invasiveness with VP-16, vincristine, taxotere or CCNU. British Journal Of Cancer, 86, 1, ppS62-S62.
• O'Driscoll L, Gammell P, Clynes M. 2002. Engineering Vero cells to secrete human insulin. In Vitro Cellular & Developmental Biology, 38, 3, pp146-153.
• Connolly L, Moran E, Larkin A, Scheffer G, Scheper R, Sarkardi B, Kool M, Clynes M. 2001. A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3. Hybridoma And Hybridomics, 20(5-6), , pp333-341.
• Meleady, P., Clynes, M.. 2001. Bromodeoxyuridine induces integrin expression at transcriptional (alpha(2) subunit) and post-transcriptional (beta(1) subunit) levels, and alters the adhesive properties of two human lung tumour cell lines.. Cell Communication And Adhesion, 8, 1, pp45-.
• Meleady P, and Clynes M. 2001. Bromodeoxyuridine increases keratin 19 protein expression at a posttranscriptional level in two human lung tumor cell lines. In Vitro Cellular & Developmental Biology-animal, 37, 8, pp536-542.
• Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L, Clynes M. 2001. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. European Journal Of Cancer, 37, 8, pp1041-1052.
• Maguire A R, Plunkett S J, Papot S, Clynes M, O'Connor R, Toughey S. 2001. Synthesis of indomethacin analogues for evaluation as modulators of MRP activity. Bioorganic & Medicinal Chemistry, 9, 3, pp745-762.
• Maguire A.R, Papot S, Ford A, Touhey S, O'Connor R, Clynes M. 2001. Enantioselective synthesis of sulindac. Synlett, 1, pp41-44.
• O'Loughlin C, Heenan M, Coyle S and Clynes M. 2000. Altered cell cycle response of drug resistant lung carcinoma cells to doxorubicin. European Journal Of Cancer, 36, 9, pp1149-1160.
• Larkin A M, Moran E, Alexander D & Clynes M. 1999. Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias. Drug Resistance In Leukemia And Lymphoma Iii, 457,, pp65-70.
• Nic Amhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, Nunez G, Scanlon K, Clynes M. 1999. Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. International Journal Of Cancer, 82, 3, pp368-376.
• McBride S, Walsh D, Meleady P, Daly N, Clynes M. 1999. Bromodeoxyuridine induces keratin protein synthesis at a posstranscriptional level in human lung tumour cell lines. Differentiation, 64, 3, pp185-193.
• Daly P, Verhaegen S, Clynes M, Kavanagh K. 1999. Culture filtrates of aspergillus fumigatus induce different modes of cell death in human cancer cell lines. Mycopathologia, 146, 2, pp67-74.
• Larkin A. M, Moran E, Alexander D, Doherty G, Connolly L, Kennedy S.M, Clynes M. 1999. A new monoclonal antibody that specifically recogised the MDR-3-encoded gene product. International Journal Of Cancer, 80, 2, pp265-271.
• Byrne D, Daly C, NicAmhlaoibh R, Howlett A, Scanlon K, Clynes M. 1998. Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug reistance. Cytotechnology, 27,, pp113-136.
• Daly N, Meleady P, Walsh D, Clynes M. 1998. Regulation of keratin and integrin gene expression in cancer and drug resitance. Cytotechnology, 27,, pp321-344.
• Larkin A.M, Moran E, Kennedy S.M, Clynes M. 1998. Investigation of multiple drug resistance (MDR) protein levels on pre and post treatment samples from breast cancer patients. British Journal Of Cancer, 78,, pp25-25.
• Moran E, LarkinA.M, Cleary I, Barnes C, Kennedy S.M, Kelehan P, Clynes M. 1998. Monoclonal antibodies raised to paraffin wax embedded archival tissue: feasibility study of their potential to detect novel antigenic markers. Journal Of Immunological Methods, 218, 1-2, pp151-159.
• Clynes M, Daly C, NicAmhlaoibh R, Cronin D, Elliott C, O'Connor R, O'Doherty T, Connolly L, Howlett A, Scanlon K. 1998. Recent developments in drug resistance and apoptosis research. Critical Reviews In Oncology Hematology, 28,, pp181-205.
• Duffy C.P, Elliott C.J, O'Connor R.A, Heenan M.M, Coyle S, Cleary I.M, Kavanagh K, Verhaegen S, O'Loughlin C.M, NicAmhlaoibh R, and Clynes M. 1998. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). European Journal Of Cancer, 34, 8, pp1250-1259.
• Dunne B.M, McNamara M, Clynes M, Shering S.G, Larkin A.M, Moran E, Barnes C, Kennedy S.M. 1998. MDR1 expression is associated with adverse survival in melanoma of the uveal tract. Human Pathology, 29, 6, pp594-598.
• McBride S, Meleady P, Baird A, Dinsdale D, Clynes M. 1998. Human lung carcinoma cell line DLKP contains 3 distinct subpopulations with different drowth and attachment properties. Tumor Biology, 19, 2, pp88-103.
• Keenan K, Dooley M, Pearson D & Clynes M. 1997. Recombinant human albumin in cell culture: evaluation of growth promoting potiential for NRK and SCC-9 cells in vitro. Cytotechnology, 24, 3, pp243-252.
• Byrne, D., Daly, C., Masterson, A., Scanlony, K., Clynes, M. 1997. The effects of down-regulation of LRP protein via LRP-targeted ribozymes and antisense RNA on the cytotoxic drug resistance of an ovarian carcinoma cell line.
• Graves R, Davies R, Owen P, Clynes M, Cleary I, & O'Beirne G. 1997. An homogeneuous assay for measuring the uptake and efflux of radiolabelled drugs in adherent cells. Journal Of Biochemical And Biophysical Methods, 34, 3, pp177-187.
• Moran E, Larkin A.M, Doherty G, Kelehan P, Kennedy S & Clynes M. 1997. New mdr-1-encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. Journal Of Clinical Pathology, 50, 6, pp465-471.
• Cleary I, Doherty G, Moran E & Clynes M. 1997. The multidrug-resistant human lung tumour cell line, DLKP-A10 expresses novel drug accumulation and sequestration systems. Biochemical Pharmacology, 53, 10, pp1493-1502.
• Cotter G, Verhaegen S, Clynes M & KavanaghK. 1997. Membrane changes associated with the early stages of apoptosis in HEp-2 cells decrease susceptibility to adherence by Candida albicans. Journal Of Medical And Veterinary Mycology, 35, 3, pp219-224.
• Heenan M, O'Driscoll L, Cleary I, Connolly L & Clynes M. 1997. Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. International Journal Of Cancer, 71, 5, pp907-915.
• Moran E, Cleary I, Larkin A.M, NicAmhlaoibh R, Masterson A, Sheper R.J, Izquierdo M.A, Center M, O'Sullivan F & Clynes M. 1997. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins in three resistant variants of the human ovarian carcinoma cell line OAW-42. European Journal Of Cancer, 33, 4, pp652-660.
• Clynes M. 1996. Proceeding of ETCS meeting on drug resistance Dublin 1995. Cytotechnology, 19,, pp175-175.
• Daly C, Coyle S, McBride S, O'Driscoll L, Daly N, Scanlon K & Clynes M. 1996. mdr-1 ribozyme-mediated reversal of the multidrug resistant phenotype in human lung cell lines. Cytotechnology, 19,, pp199-205.
• Heenan M, Kavanagh K, Redmond A, Maher M, Dolan E, O'Neill P, Moriarty M & Clynes M. 1996. Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines. Cytotechnology, 19,, pp137-242.
• Keenan J, Doherty G, & Clynes M. 1996. Separation of growth-stimulating activity of BSA fraction V from the bulk of albumin using heparin sepharose chromatography. Cytotechnology, 19, 1, pp63-72.
• McNamara M, Clynes M, Dunne B, NicAmhlaoibh R, Lee, W.R, Barnes C & Kennedy S.M. 1996. Multidrug resistance in ocular melanoma. British Journal Of Ophthalmology, 80, 11, pp1009-1012.
• Keenan J & Clynes M. 1996. Replacement of transferrin by simple iron compounds for MDCK cells grown and subcultured in serum-free medium. In Vitro Cellular & Developmental Biology, 32,, pp451-453.
• O'Driscoll L, Kennedy S, McDermott E, Kelehan P, & Clynes M. 1996. Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue. European Journal Of Cancer, 32A, 1, pp128-133.
• Clynes M, Heenan M, McBride S, Cleary I, Doherty G, O'Driscoll L & Moran E. 1995. Multiple drug resistance in variants of a human lung line exposed to adriamycin and VP-16. Journal Of Experimental & Clinical Cancer Research, 14,, pp15-16.
• Cleary I, Grant G, Moran E, Doherty G, O'Driscoll D, & Clynes M. 1995. Adriamycin transport sutides in an MDR human bladder-carcinoma cell-line. Journal Of Experimental & Clinical Cancer Research, 14,, pp55-57.
• Meleady P, & Clynes M. 1995. Growth of a human lung cell line in a defined serum-free medium. Journal Of Experimental & Clinical Cancer Research, 14,, pp65-67.
• Moran E, Cleary I, Izquierdo M, Scheper R.J, O'Sullivan F, U. Gilvarry & Clynes M. 1995. Preliminary studies comparing an intrinsically low-level resistant cell line, OAW42-SR and a low-level doxorubinin-selected resistant variant OAW42-A1 stable in the absence of drug. Journal Of Experimental & Clinical Cancer Research, 14,, pp58-59.
• Redmond A, Moran E & Clynes M. 1993. Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A. European Journal Of Cancer, 29A, 8, pp1078-1081.
• Clynes M, Heenan M, & Hall K. 1993. Human cell lines as models for multidrug resistance in solid tumours. Cytotechnology, 12,, pp231-256.
• Clynes M. 1993. Special issue on multiple-drug resistance in cancer-cellular molecular and clinical approaches-introduction. Cytotechnology,, ppR7-R8.
• O'Driscoll L, Daly C, Saleh M, Clynes M. 1993. The use of reverse transcriptase-polymerase chain-reaction (RT-PCR) to investigate specific gene-expression in multidrug-resistanct cells. Cytotechnology, 12,, pp289-314.
• Martin A, & Clynes M. 1993. Comparison of 5 microplate colorimetric assays for invitro cytotoxicity testing and cell proliferation assays. Cytotechnology, 11, 1, pp49-58.
• Pessina A, Mineo E, Gribaldo L, Mancina G, Neri M, Moran E, Cleary I & Clynes M. 1993. Susceptibility of leukaemia-cell lines to quinolones and induction of resistance to ciprofloxacin in WEHI-3B (D+) leukemia cells. European Journal Of Cancer, 6, 5, pp291-297.
• Clynes M. 1993. Cellular models for multiple drug resistance in cancer. In Vitro Cellular & Developmental Biology-animal, 29,, pp171-179.
• Carey A, Dooley M, Weedle R & Clynes M. 1993. Production of autostimulatory growth-factors by the human carcinoma line RPMI 2650. In Vitro Cellular & Developmental Biology, 29, 2, pp153-160.
• CLYNES, M., REDMOND, A., MORAN, E., GILVARRY, U. 1992. Multiple drug-resistance in a variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology, 10, 1, pp75-89.
• Law E, Gilvarry U, Lynch V, Gregory B, Grant G & Clynes M. 1992. Cytogenetic comparison of 2 poorly differentiated human lung squmous cell carcinoma lines. Cancer Genetics And Cytogenetics, 59, 2, pp111-118.
• Clynes M, Martin A. 1991. Acid-phosphatase-end-point for invitro toxicity tests. In Vitro Cellular & Developmental Biology, 27,, pp183-184.
• O'Leary R, Gregory B, Cary B, McGlinchey E, O'Toole A, Clynes M, O'Connor B. 1991. Factors influencing protease levels in animal-cells invitro. Biochemical Society Transactions, 19, 1, ppS26-S26.
• Redmond A, Law E, Gilvarry U & Clynes M. 1990. Establishment of two new multi-drug resistant variants of the human tumour line Hep-2. Cell Biology And Toxicology, 6, 3, pp293-302.
• Gilvarry U, Farrell D, Lynch V, Moriarty M, Dooley M, Law E & Clynes M. 1990. Cytological differences between normal and malignant human cell populations in culture. Cancer Research, 50, 11, pp3390-3393.
• McDonnell, S., Dooley, M., Clynes, M. 1989. Growth-factors produced by human carcinoma-cells in culture. Biochemical Society Transactions, 17, 3, pp594-595.
• Allan, G., Dolley, M., Clynes, M., Headon, DR. 1989. Hormonal-regulations of epidermal growth-factor receptor gene in T47D and A431 cells. Biochemical Society Transactions, 17, 2, pp407-407.
• Allan, G., Dooley, M., Gregory, B., Clynes, M., Headon, DR. 1988. Hormonal-regulation of epidermal growth-factor receptor gene in T47D breast-cancer cells. Biochemical Society Transactions, 16, 2, pp173-173.
• McDonnell, S., Clynes, M. 1986. Conditioning factors affecting growth of human-skin keratinocytes. British Journal Of Cancer, 53, 3, pp439-439.
• Murphy, E, Clynes, M. 1985. Effect of Bovine-milk on growth of animal-cells in culture. Biochemical Society Transactions, 13, 2, pp474-475.
• McDonnell, S., Moriarty, M., Clynes, M. 1985. Growth in culture of epithelial-cells from normal and malignant human-skin. Irish Journal Of Medical Science, 154, 11, pp444-444.
• McDonnell, S., Moriarty, M., Clynes, M. 1984. Inhibition of fibroblast contamination in cultures of human epithelial-cells. Biochemical Society Transactions, 12, 3, pp436-.
• McManus, V., Clynes, M. 1984. Stimulation by feeder layers of human tumor-cell colony formation in agar. Biochemical Society Transactions, 12, 3, pp435-435.
• Clynes, M., Moriarty, MJ. 1982. Interference by a yeast contaminant in human-tumor agar colony formation assay. Irish Journal Of Medical Science, 151, 4, pp132-132.
• Okennedy, R., Smyth, H., Corrigan, A., Clynes, M. 1982. Total and surface-located Sialic-acid levels in normal and Leukemic Lymphocytes- relationship to T-cell and B-cell nature and to location Invivo. European Journal Of Cancer, 18, 2, pp437-446.
• Clynes, M., Hurley, MP. 1980. Chromosome analysis-improved metaphase yields following Thymidine synchronization. Irish Journal Of Medical Science, 149, 2, pp78-79.
• Clynes, M. 1979. Folate degradation by normal and tumor-cells in culture. Irish Journal Of Medical Science, 148, 3, pp107-107.
• Clynes, M., Duke, EJ. 1976. Effect of Polyinosinic acid-polycytidylic acid on establishment, and on spontaneous and chemical transformation of balb-C mouse-embryo cells in culture. Biochemical Society Transactions, 4, 5, pp897-899.
• Clynes, M., Duke, EJ. 1976. Altered pyrimidine-salvage metabolism in a 5-Flurouracil-resistant mutant of drosophila-melanogaster. Biochemical Society Transactions, 4, 5, pp900-901.

Selected Books

• Prof Martin Clynes. Multiple Drug Resistance in Cancer 2, Kluwer Publishers, 1998.
• Prof Martin Clynes. Animal Cell Cultur etechniques (Springer Laboratory Manual), Springer, 1998.
• Prof Martin Clynes. Multiple Drug Resistance in Cancer ¿ Cellular, Molecular and Clinical, Kluwer Publishers, 1994.

Reviews

• Prof Martin Clynes. .

Selected Non-peer Reviewed Journals

• Rajpal, R ., Dowling, P., Meiller, J., Murphy, WG., O'Connor, R., Anderson, KC., Murphy, P., Clynes, M., O'Gorman, P. 2009. Personalised medicine- the use of proteomics biomakers to predict response to thalidomide in multiple Myeloma.; JUN 04-07, 2009,Berlin, GERMANY [14th Annual Meeting of the European-Hematology-Association]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL., 94, pp26-26.
• Germano, S., Kennedy, S., Hughes, L., McDonnell, S Mehta, JP., Doolan, P., Clynes, M., Driscoll, LO. 2009. Characterisation of neuronal calcium sensor-1 (NCS-1) as a novel prognostic biomaker with potential therapeutic implications for Triple negative breast cancer.;MAY 07-09, 2009, Brussels, BELGIUM, [IMPAKT Breast Cancer Conference 2009]. ANNALS OF ONCOLOGY, 20, pp49-50.
• Kinsella, P., Howley, R., Farrell, M., Clynes, M., Amberger-Murphy, V. 2009. MicroRNA Expression in Early Passage Primary High-Grade Glioma Cell Lines and Possible Role in Glioma Invasion; JUN 11-14, 2009, San Antonio, TX, [85th Annual Meeting of the American-Association-of-Neuropathologists]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 68, pp30-30.
• Tryfonopoulos, D., O'Donovan, N., Corkery, B., Collins, D., Clynes, M., Crown, J. 2009. Dasatinib improves response to chemotherapy in triple negative breast cancer cells; MAY 07-09, 2009 ,Brussels, BELGIUM, [IMPAKT Breast Cancer Conference 2009]. ANNALS OF ONCOLOGY, 20, pp43-43.
• Kennedy, SM., Tracey, D., Doolan, P., Mehta, JP., Clynes, M., O'Driscoll, L. 2009. Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome; MAR 07-13, 2009, Boston, MA, [98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology]. MODERN PATHOLOGY, 22, pp212-212.
• Kennedy, SM., Tracey, D., Doolan, P., Mehta, JP., Clynes, M., O'Driscoll, L. 2009. Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome; MAR 07-13, 2009, Boston, MA, [98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology]. LABORATORY INVESTIGATION, 89, pp212-212.
• Browne, B., Crown, J., Clynes, M., Duffy, MJ., Slamon, D., O'Donovan, N. 2008. Alternative receptor tyrosine kinase signalling in trastuzumab resistant HER-2 positive breast cancer cells.,SEP 12-16, 2008, Stockholm, SWEDEN. [ 33rd European-Society-for-Medical-Oncology Congress]. ANNALS OF ONCOLOGY, 19, pp47-48.
• Corkery, B., O'Donovan, N., Clynes, M., Crown, J. 2008. Gefitinib (G) potentiates the activity of Carboplatin (P) and Docetaxel (D) in triple negative breast cancer(TNBC).,SEP 12-16, 2008, Stockholm, SWEDEN,[33rd European-Society-for-Medical-Oncology Congress]. ANNALS OF ONCOLOGY, 19, pp52-52.
• Eustace, AJ., Crown, J., Clynes, M., O'Donovan, N. 2008. Preclinical evaluation of dasatinib in melanoma cell lines., JUL 05-08, 2008,Lyon, FRANCE, [20th Meeting of the European-Association-for-Cancer-Research]. EJC SUPPLEMENTS, 6, pp112-112.
• Tryfonoooulos, D., Corkery, B., O'Donovan, N., Clynes, M., Crown, J. 2008. Possible targets for dasatinib sensitivity in triple negative breast cancer., APR 15-19, 2008, Berlin, GERMANY, [6th European Breast Cancer Conference]. EJC SUPPLEMENTS, 6, pp220-220.
• Kumar, N., Maurya, P., Ganunell, P., Dowling, P., Clynes, M., Meleady, P. 2008. Proteomic profiling of secreted proteins from CHO cells using surface-enhanced laser desorption ionization time-of-flight mass spectrometry., JAN 14-18, 2007, JAN 14-18, 2007,[1st International Conference on Biomolecular Engineering (ICBE)]. BIOTECHNOLOGY PROGRESS, 24, pp273-278.
• Corkery, B., O'Donovan, N., Clynes, M., Crown, J. 2007. Gefitinib enhances response to chemotherapy in triple-negative Breast Cancer (BrCa)., SEP 23-27, 2007, Barcelona, SPAIN, [14th European Cancer Conference (ECCO 14)]. EJC SUPPLEMENTS, 5, pp185-185.
• Keenan, J., Pearson, D., Clynes, M. 2007. Screening strategies for iron chelators in serum free media., JUN 05-08, 2007, Harrogate, ENGLAND, [19th Meeting of the European-Society-for-Animal-Cell-Technology (ESACT)]. CELL TECHNOLOGY FOR CELL PRODUCTS., pp785-788.
• O'Donovan, N., Clynes, M., Crown, J. 2006. Dual targeting of ErbB1 and ErbB2 enhances response to chemotherapy in ErbB2 overexpressing breast cancer cell lines., DEC 14-17, 2006, San Antonio, TX, [29th Annual San Antonio Breast Cancer Symposium]. BREAST CANCER RESEARCH AND TREATMENT, 100, ppS105-S105.
• Breen, L., Heenan, M., Amberger-Murphy, V., Clynes, M. 2006. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines., SEP 07-08, 2006, Dublin, IRELAND,[International Conference on Global mRNA and Protein Analysis]. ANTICANCER RESEARCH, 27, pp1361-1364.
• Collins, DM., O'Connor, R., O'Donovan, N., Clynes, M., Crown, J. 2006. Lapatinib inhibits P-glycoprotein (P-GP) and synergistically enhances taxane cytotoxicity in P-GP plus cell lines., SEP 29-OCT 03, 2006, Istanbul, TURKEY,[30th Congress of the European-Society-for-Medical-Oncology]. ANNALS OF ONCOLOGY, 17, pp57-57.
• Dowling, P., Maurya, P., Meleady, P., Glynn, SA., Dowd, AJ., Henry, M., Clynes, M. 2006. Purification and identification of a 7.6-kDa protein in media conditioned by superinvasive cancer cells.,SEP 07-08, 2006, Dublin, IRELAND,[International Conference on Global mRNA and Protein Analysis]. ANTICANCER RESEARCH, 27, pp1309-1317.
• Kumar, N., Gammell, P., Clynes, M. 2006. Proliferation control strategies to improve productivity and survival during CHO based production culture - A summary of recent methods employed and the effects of proliferation control in product secreting CHO cell lines., SEP 07-08, 2006, Dublin, IRELAND. [International Conference on Global mRNA and Protein Expression Analysis Resarch-Applications in Cancer and Other Diseases and in Biopharmaceutical Production]. CYTOTECHNOLOGY, 53, pp33-46.
• Maurya, P., Meleady, P., Dowling, P., Clynes, M. 2006. Proteomic approaches for serum biomarker discovery in cancer., SEP 07-08, 2006, Dublin, IRELAND,[International Conference on Global mRNA and Protein Analysis]. ANTICANCER RESEARCH, 27, pp1247-1255.
• Mehta, JP., O'Driscoll, L., Barron, N., Clynes, M., Doolan, P. 2006. A microarray approach to translational medicine in breast cancer: How representative are cell line models of clinical conditions?.,SEP 07-08, 2006, Dublin, IRELAND,[International Conference on Global mRNA and Protein Analysis]. ANTICANCER RESEARCH, 27, pp1295-1300.
• Murphy, L., Clynes, M., Keenan, J. 2006. Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma., SEP 07-08, 2006, Dublin, IRELAND, [International Conference on Global mRNA and Protein Analysis]. ANTICANCER RESEARCH, 27, pp1277-1284.
• O'Sullivan, F., Clynes, M. 2006. Limbal stem cells, a review of their identification and culture for clinical use., SEP 07-08, 2006,Dublin, IRELAND,[International Conference on Global mRNA and Protein Expression Analysis Research-Applications in Cancer and Other Diseases and in Biopharmaceutical Production]. CYTOTECHNOLOGY, 53, pp101-106.
• Piskareva, O., Clynes, M., Barron, N. 2006. Detection and cloning of LINE-1 elements in CHO cells.,SEP 07-08, 2006,Dublin, IRELAND, [International Conference on Global mRNA and Protein Expression Analysis Resarch-Applications in Cancer and Other Diseases and in Biopharmaceutical Production]. CYTOTECHNOLOGY, 53, pp75-80.
• Walsh, N., Kennedy, S., Larkin, A., Roy, S., Seong, WO., Gullo, G., Ballot, J., Clynes, M., Crown, J., O'Driscoll, L. 2006. MDR1/P-glycoprotein and MRP-1 protein expression in pancreatic (CaP) & non-small cell lung cancers (NSCLC)., SEP 29-OCT 03, 2006, Istanbul, TURKEY,[30th Congress of the European-Society-for-Medical-Oncology]. ANNALS OF ONCOLOGY, 17, pp64-65.
• O'Leary, M., O'Connor, R., Roy, S., Ballot, J., Ooi, W., Fennelly, D., Sheehan, L., Collins, C., Clynes, M., Crown, J. 2004. Phase I trial of the multi-drug resistance (MDR) protein-1 (MRP-1) modulating agent sulindac (S) plus epirubicin (E) in patients (pts) with advanced cancer., JUN 05-08, 2004, New Orleans, LA., [40th Annual Meeting of the American-Society-of-Clinical-Oncology]. JOURNAL OF CLINICAL ONCOLOGY, 22, pp2129-.
• Cronin, D., Daly, C., O'Doherty, T., Heenan, M., Scanlon, KJ., Clynes, M. 2003. Construction and transfection of a ribozyme targeting human caspase-3.,JUL 07-08, 2003, Dublin, IRELAND, [1st National-Institute-for-Cellular-Biotechnology Conference]. ANTICANCER RESEARCH, 24, pp425-431.
• Keenan, J., Liang, Y., Clynes, M. 2003. Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants., JUL 07-08, 2003,Dublin, IRELAND,[1st National-Institute-for-Cellular-Biotechnology Conference]. ANTICANCER RESEARCH, 24, pp433-440.
• O'Connor, R., Heenan, M., Connolly, L., Larkin, A., Clynes, M. 2003. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer., JUL 07-08, 2003, Dublin, IRELAND, [1st National-Institute-for-Cellular-Biotechnology Conference]. ANTICANCER RESEARCH, 24, pp457-464.
• O'Driscoll, L., Cronin, D., Kennedy, SM., Purcell, R., Linehan, R., Glynn, S., Larkin, A., Scanlon, K., McDermott, EW., Hill, AD., O'Higgins, NJ., Parkinson, M., Clynes, M. 2003. Expression and prognostic relevance of Mcl-1 in breast cancer., JUL 07-08, 2003, Dublin, IRELAND, [1st National-Institute-for-Cellular-Biotechnology Conference]. ANTICANCER RESEARCH, 24, pp473-482.
• O'Driscoll, L., Gammell, P., Clynes, M. 2003. Investigation of the mechanisms associated with loss of glucose responsiveness in beta cells., JUL 08-11, 2003, DUBLIN, IRELAND, [9th Congress of the International-Pancreas-and-Islet-Transplant-Association]. TRANSPLANTATION, 76,
• O'Driscoll, L., Gammell, P., O'Sullivan, F., Clynes, M. 2003. Regulated differentiation of murine teratocarcinoma cells to cells expressing pancreatic islet proteins.,JUL 08-11, 2003, DUBLIN, IRELAND, [9th Congress of the International-Pancreas-and-Islet-Transplant-Association]. TRANSPLANTATION, 76, pp130-.
• O'Driscoll, L., Gammell, P., Clynes, M. 2003. Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development., JUN 28-JUL 02, 2003, Forteleza, BRAZIL, [8th Congress of the Brazilian-Transplantion-Society]. TRANSPLANTATION PROCEEDINGS, 36, pp1151-1158.
• O'Driscoll, L., Gammell, P., Clynes, M. 2003. Mechanisms associated with loss of glucose responsiveness in beta cells.,JUN 28-JUL 02, 2003, Forteleza, BRAZIL, [8th Congress of the Brazilian-Transplantion-Society]. TRANSPLANTATION PROCEEDINGS, 36, pp1159-1162.
• Larkin, A., Moran, E., Alexander, D., Clynes, M. 1998. Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias., MAR 04-07, 1998, AMSTERDAM, NETHERLANDS, [3rd International Symposium on Durg Resistance in Leukemia and Lymphoma]. DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 457, pp65-70.
• Daly, C., Coyle, S., McBride, S., ODriscoll, L., Daly, N., Scanlon, K., Clynes, M. 1995. mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines., SEP 20-23, 1995, DUBLIN, IRELAND, [International Meeting on Drug Resistance in Cancer]. CYTOTECHNOLOGY, 19, pp199-205.
• Heenan, M., Kavanagh, K., Redmond, A., Maher, M., Dolan, E., ONeill, P., Moriarty, M., Clynes, M. 1995. Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines., SEP 20-23, 1995, DUBLIN, IRELAND,[International Meeting on Drug Resistance in Cancer]. CYTOTECHNOLOGY, 19, pp237-242.
• Otoole, A., Meleady, P., Clynes, M. 1995. Agitation resistance of Chinese hamster ovary cells., JAN 05-06, 1995, EDINBURGH, SCOTLAND. 1995 ICHEME RESEARCH EVENT - FIRST EUROPEAN CONFERENCE FOR YOUNG RESEARCHERS IN CHEMICAL ENGINEERING,, 1 and 2, pp917-919.
• Cleary, I., Grant, G., Moran, E.,Doherty, G., Odriscoll, D., Clynes, M. 1994. Adriamycin transport studies in an MDR human bladder-carcinoma cell-line.,OCT 09-12, 1994, Verona, ITALY, [41st International Congress of the European-Tissue-Culture-Society]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 14, pp55-57.
• Clynes, M., Heenan, M., McBride, S., Cleary, I., Doherty, G., Odriscoll, L., Moran, E. 1994. Multiple -drug resistance in variants of a human line exposed to adriamycin and VP-16., OCT 09-12, 1994., Verona, ITALY., [41st International Congress of the European-Tissue-Culture-Society]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 14, pp15-16.
• Meleady, P Clynes, M. 1994. Growth of a human lung-cell line in a defined serum-free medium., OCT 09-12, 1994, Verona, ITALY,[41st International Congress of the European-Tissue-Culture-Society]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 14, pp68-70.
• Moran, E., Cleary, I., Izquierdo, M., Scheper, RJ., O'Sullivan, F., Gilvarry, U., Clynes, M. 1994. Preliminary studies comparing an intrinsically low-level resistant cell line, OAW42-SR and a low-level,doxorubicin-selected resistant variant, OAW42-A1 stable in the absence of drug., OCT 09-12, 1994, Verona, ITALY,[41st International Congress of the European-Tissue-Culture-Society]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 14, pp58-59.

• , , , - ,